Ac immune reports full-year 2020 financial results and provides 2021 r&d outlook

Lausanne, switzerland, march 23, 2021 (globe newswire) -- ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the year ended december 31, 2020. the company also provided an overview of its execution strategy and anticipated clinical and preclinical milestones for 2021, as well as the strong progress being made across its broad portfolio of therapeutic and diagnostic product candidates.
ACIU Ratings Summary
ACIU Quant Ranking